Shareholdings
| Concept |
As at 2025-03-31 |
2024-04-01 to 2025-03-31 |
|---|---|---|
| Shareholdings | ||
| Reporting company | ||
| Investment shares held for purposes other than pure investment | ||
| Shares not listed | ||
| Number of issues |
8
xbrli:pure
|
— |
| Carrying amount |
521,000,000
JPY
|
— |
| Number of issues whose number of shares increased | — |
1
xbrli:pure
|
| Total acquisition cost for increased shares | — |
300,000,000
JPY
|
| Reason for increase in number of shares | — |
遺伝子治療薬の受託分析におけるベンチャー企業として、協業により当社の事業拡大につながると判断したため
|
| Number of issues whose number of shares decreased | — |
xbrli:pure
|
| Total sale amount for decreased shares | — |
JPY
|
| Shares other than those not listed | ||
| Number of issues |
6
xbrli:pure
|
— |
| Carrying amount |
2,178,000,000
JPY
|
— |
| Number of issues whose number of shares increased | — |
1
xbrli:pure
|
| Total acquisition cost for increased shares | — |
316,000,000
JPY
|
| Reason for increase in number of shares | — |
クロマトグラフィおよび関連消耗品であるカラムのメーカー兼商社として、協業により当社の事業拡大につながると判断したため
|
| Number of issues whose number of shares decreased | — |
2
xbrli:pure
|
| Total sale amount for decreased shares | — |
JPY
|